Fourth Quarter & FY21 Business Update

Mach7 Delivers 95% Sales Order Growth for FY21

Financial Highlights:

• Record sales orders FY21 $25.6M; up 95% (TCV1); Q4 $4.4M;
• Record cash receipts FY21 $21.0M; up 23%; Q4 $4.6M
• Positive operating cash FY21 $1.2M; Q4 near breakeven -$0.06M
• Cash on hand 30 June 2021 $18.4M
• Revenues for FY21 expected to be $19M-$19.5M
• Annual recurring revenue (ARR) run-rate $13.4M; up 105%

Mach7 Licenses eUnity Viewer to Advocate Aurora

AAH now utilizing the full suite of Mach7 solutions

Melbourne, Australia; 19 July 2021: Mach7 Technologies Limited (“Mach7” or the “Company”) (ASX:M7T), a company specialising in innovative medical imaging solutions for healthcare providers, today announced it has licensed its eUnity universal viewing solution to Advocate Aurora Health (AAH). The license contract is valued at $4.3 million, which includes a software license fee, professional services, and an initial five-year support term. Of this value, Mach7 expects to recognize $1.5 million - $1.7 million in FY22, with the remainder being recognised evenly from FY23 – FY27. The contract provides for volume expansion pricing and the ability for AAH to extend the initial term at agreed pricing.

AAH currently utilizes the Mach7 Vendor Neutral Archive (VNA) for storage and image data management. This agreement will extend Mach7’s product presence at AAH with the Mach7 eUnity Viewer, which will serve as a universal viewer for multiple departments across the AAH network. The eUnity viewer will also be deployed as a full diagnostic viewer and, in conjunction with Mach7’s Universal Worklist, will serve a back-up PACS solution for downtime occurrences, including planned maintenance and unplanned events.

3 June 2021

From today's presentation:

• Cash on hand $18M, no debt, no capitalized R&D (all expensed as incurred)
• Cash flow positive Q3 YTD $1.2M (FY2020: $4.5M)
• Shares on issue 235.65M, current market capitalization $245M

"... Mach7 competes in all segments of the Radiology IT market, except Standalone RIS & Image Exchange ..."

License fees from:

• Capital License (“Capex”)
• Subscription License (“SAAS”)

12 April 2021

Highlights:

• Record quarterly cash receipts $8.4M (98% increase over Q2)
• Q3 positive cash flow from operations $3.3M (375% increase over Q2)
• Cash on hand has increased to $18M (from $14.4M Q2)
• Q3 sales orders $12.8M (Q2 $7.6M), $23.6M YTD (TCV1)
• Customer deployments continue to make good progress
• 2021 Global Enterprise Imaging Solutions Product Leadership Award by Frost andSullivan

Positive Progress at Hospital Authority of Hong Kong Leads to Additional Sales Opportunities

Highlights:

• Purchase orders of $4.2M this financial year to date
• $10M (67%) of original contract value has now been ordered and delivered
• Software implementation near completion
• Successes leading to new opportunities at HAHK, valued at $1.8M so far

Adventist Health Significantly Expands its Enterprise Imaging Strategy with Mach7

Highlights:

• Adventist Health System licenses Mach7 PACS solution
• Total new contract value A$7.9 million
• The expanded relationship will see Mach7 solutions deployed across 22 hospitals

21 January 2021

Second Quarter FY21 Business Update

Highlights:

• Record Q2 cash receipts $4.25M
• Operating synergies from the Client Outlook acquisition beginning to be realised
• Cash flow from operations -$0.3M
• Strong financial position with $14.4M cash on hand and no debt
• Q2 sales orders $7.6M
• 4 significant and successful software deployments completed across the USA

Mach7 Signs 7-year Contract with Trinity Health for eUnity Enterprise Viewer

Highlights:

• License for eUnity Enterprise Viewer contracted with Trinity Health (USA) for 7years
• eUnity E nterprise Viewer contract value A$5.26 million
• Potential contracts to follow for Mach7’s VNA and diagnostic viewing platform

THIRD QUARTER FY20 BUSINESS UPDATE

Highlights:

• New sales orders of $0.8 million
• Two new teleradiology customers go live on Mach7’s Platform•COVID-19 sees sales cycle lengthened but creates new remote reading opportunity
• Q3 closes with $22.6 million cash, no debt
• Strong revenue growth (45%) expected for FY20
• EBITDA profitable and positive free cash flow results expected for FY20

Sales Orders & Successful Deployments

The Company completed $0.8 million of new sales orders for the quarter, largely from its existing customer install base. The sales were predominantly for technology licenses and professional services and as such, are expected to convert to revenue well within one year.

During the quarter, Mach7 had two of its newest customers go live on the Mach7 Platform:

Colorado Imaging Associates, P.C. (“CIA”)

CIA very recently went live on Mach7’s Enterprise Imaging Platform. CIA provides professional radiology services to hospitals, medical centers, outpatient imaging centers and specialty practices throughout Colorado (and Wyoming). CIA is archiving studies and results for 11 sites using the Mach7 Platform, with plans to bring additional sites on board including one with new 3D breast tomosynthesis in May 2020. Additional clinical workflows have been configured using the Mach7 software and will be brought live once the PACS side is ready. CIA’s Director of IT has stated he isimpressed with the ease in which Mach7 can configure workflows in the Platform.

Adventist Health Tulare (“Tulare”)

Tulare Hospital went live on Mach7’s Diagnostic Studio along with Client Outlook’s zero footprint diagnostic viewing platform during March. Tulare is a 101-bed hospital located in Tulare, CA and is part of Adventist Health Central Valley Network. The Mach7 solution provided Tulare with a modern and integrated teleradiology PACS workflow. The group of 8 Radiologists are using the Mach7Platform for daytime teleradiology and will utilise the Platform (together with Client Outlook’s eUnity ASX Announcementviewer) to read onsite, at a neighbouring hospital or from home. Tulare’s Chief Radiologist is ecstatic with the flexibility the system has provided for exam access. As a result, the customer has quickly expanded the go live beyond CT’s, to read all modalities. The Chief Radiologist was extremely excited to extract himself from Tulare’s aging PACS and is looking to expand the Mach7 solution to other sites within the Adventist Health network.

COVID-19 Business Update

Further to the Company’s shareholder update on 19 March 2020, Mach7 today provides more information on the impact the global COVID-19 pandemic is having on the business and the healthcare industry more broadly:

Demand for Mach7 software continues

There will be a pent-up demand for elective procedures once the pandemic subsides and hospital revenue should rebound. Whilst the timing of this expected rebound is still uncertain, the demand for Mach7’s software continues. The sales pipeline is stable and being monitored closely.

Sales cycle has lengthened

COVID-19 has created tremendous short-term impacts on the healthcare industry. Revenue for hospitals, Independent Delivery Networks (IDNs) and private practices is down, although the actual percentage of revenue loss varies greatly across healthcare providers. This temporary loss of revenue is driving a pause in the buying market for new projects. This is lengthening the sales cycle for Mach7’s enterprise imaging platform and Mach7 expects the sales cycle to be longer than usual for at least through the rest of this fiscal year, and likely into Q1 of FY21.

New market opportunity for Mach7 software

The need for hospitals to invest in Business Continuity services and the ability for clinicians to perform work from home has become more acute than ever. There is a distinctly different requirement in software capability between remote reviewing/preliminary reading and diagnostic reading remotely. Preliminary reading is commonplace and a market that has already been saturated. However remote diagnostic reading capability is largely being served by outdated technology today and provides Mach7 with a unique market opportunity. The Mach7 softwaresolution is uniquely positioned, both in functionality and in interoperability capabilities, to provideclinicians with cutting edge technology for remote diagnostic reading, allowing both the clinical and technical components of the organizations to be successful. ...

Q3 Closes with Strong Financial Position

The Company reported $1.3 million free cash outflows for the quarter, and $0.9 million of positive free cash flows for the nine months year to date. Notably, this quarter includes a one-off payment of $0.6 million to a reseller which related to sales made in a previous quarter. This Q3 result was in-line with internal expectations, with Q3 being seasonally the weakest cash flow quarter of the year. The Company closed the quarter with $22.6 million (Q2: $23.3 million) cash reserves and no debt.

12-month Free Cashflow Positive Target Update

In March 2019, the Company announced it expects to be free cashflow breakeven for the next 12-months, i.e. to the end of February 2020. For the 10-months ending 31 December, the Company reported $2.4 million of positive free cash flows, and today is still free cash flow positive and is therefore highly likely to be free cash flow positive for the 12 months ending 29 February 2020.

Cash Reserves

The financial position of the Company is strong with $23.3 million in cash, debt free and therefore well positioned to take advantage of organic and acquisitive growth opportunities. During the half year Mach7 successfully completed a private placement to institutional and other sophisticated investors, raising $20 million (before brokerage costs).

Mach7 Delivers Positive EBITDA and NPAT, Revenue growth +158%

H1 FY20 Highlights:

• EBITDA $2.3 million, growth of $5.2 million or 176%;
• NPAT $0.7 million, growth of $5.1 million or 115%;
• Revenue $9.1 million, growth of $5.6 million or 158%;
• Business well capitalised with $23.3 million cash, debt free and positioned for future growth;
• Strong growth driven by new customer contracts and continued growth in CARR
• Growing sales pipeline including higher value RFP opportunities

Investor PresentationMorgan Stanley – Alpha ex-100 Conference

24 October 2019

Mach7 Competitive Advantages

1. Customer controls their own data– easy user interface and rules engine
2. Interoperability across the enterprise(connecting all systems, across all ‘ologies’)
3. Very Little Hardware (Lowers cost and accelerates install)
4. Ease of Install; Quality (& Fast) Support
5. Attractive Price Point

FIRST QUARTER FY20 BUSINESS UPDATE

Strongest Quarterly Cash Result in M7T History

Q1 Highlights:

• $1.7 million positive operating cash flows
• $4.7 million cash receipts from customers
• $4.3 million cash at bank
• Largest US sales order won $5.7 million
• $10.7 million service and support fees under contract, including $8.5 million CARR

Mach7 Awarded US Patent for its Management Studio

Melbourne, Australia; 2 October 2019: Mach7 Technologies Limited (ASX:M7T), a company specialising in innovative data management solutions for healthcare providers, today announced it has been awarded a United States Patent for its “Dynamic Media Object Management System”.

The patented technology is commercially available in Mach7 Management Studio, the core of Mach7’s enterprise imaging platform.

The patent focuses on Mach7’s unique technology in communicating medical imaging data. Specifically, this patent is centred around Mach7’s unique smart routing techniques and the ability to use specialized adaptors to create custom workflows to solve complex interoperability issues in the medical imaging industry.

Core to the Mach7 Platform, this technology strengthens Mach7’s position in managing enterprise imaging data across distributed health systems and disparate clinical applications.

Mach7’s Management Studio is able to dynamically localize and communicate the components of imaging studies without needing to receive the entire procedure resulting in dynamic media distribution with limited latency and added capabilities to imaging IT administrators.

Ravi Krishnan, Founder of Mach7 Technologies and inventor of the patent , commented “This Patent award underscores Mach7’s breadth of expertise in enterprise imaging architectures and software design. This patent is core to our ability to solve  interoperability issues across the enterprise and further underscores our long-standing commitment to an enterprise-first technology platform.”

Melbourne, Australia; 22 August 2019: Mach7 Technologies Limited (“Mach7” or “the Company”) (ASX:M7T) is pleased to announce it has signed a software license agreement with St. Teresa’s Hospital, a private hospital located in Kowloon, Hong Kong. The agreement has an estimated total contract revenue value of $950k across a 5-year term for the Company.

St. Teresa’s has licensed Mach7’s Enterprise Imaging Platform, Universal Worklist, QC Workflow and migration engine to consolidate its existing siloed Picture Archiving Communication Systems (PACS) into a single system. This initiative is expected to improve radiologist productivity through rapid access to relevant prior patient images, enabling both reading and quality control in different environments through web-based applications. This deal marks Mach7’s breakthrough into Hong Kong’s private hospital space, following on from Mach7’s contract with Hong Kong’s public hospital provider, Hospital Authority, in 2018.

“This deal represents the first Mach7 PACS replacement in Hong Kong for the private sector,” said Mike Lampron, Mach7 Managing Director. “We are gaining positive momentum in this region and this deal confirms the need for a flexible PACS solution that emphasises interoperability and can provide image access to all clinicians. St. Teresa’s is a well-respected hospital in Hong Kong, and we are delighted to help them expand their capabilities to better meet their patients' needs.”

About St. Teresa’s Hospital:

St. Teresa’s Hospital is a private Catholic Hospital located in Kowloon, Hong Kong. The 1050-bed hospital is a member of the Hong Kong Private Hospitals Association and offers a wide range of specialisations, including ENT, Orthopaedics, Cardiology, Neurology & Neurosurgery, Reconstructive Surgery, and more. www.sth.org.hk.

14 August 2019 New Contracts Affirm Sales Strategy

New contracts recently signed:

• Colorado Imaging Associates
• UW Medicine
• Sentara Halifax Regional Hospital

Mach7 Technologies Limited

(Mach7 or the Company) (ASX:M7T) is pleased to announce it has recently won three new contracts with a combined total contract value of approximately A$0.5 million.

Sales Strategy Progress

These new contracts further consolidate a strong sales quarter, following the $5.7  million minimum total contract value deal with Advocate Aurora Health announced last month.

Importantly, the contracts demonstrate the Mach7 Platform can be used to provide a complete enterprise imaging strategy, including a modern approach to radiology PACS, whilst solving interoperability issues healthcare organizations are facing with their existing technologies.

These contracts are further proof that hospital consolidation and supply chain optimisation are growth catalysts for the enterprise imaging market. Mach7 is well-positioned to assist potential clients through every stage of their enterprise journey and the Company is continuing to make inroads with both new and existing customers to realize this goal. These recent wins, as outlined below, affirm Mach7’s commercial strategy and that the market is responding to the innovative solutions offered by Mach7

Colorado Imaging Associates

Colorado Imaging Associates (CIA) is a radiology services company based in Golden, Colorado. CIA have purchased the Mach7 Platform to augment its current technology with smart routing and niche workflow capabilities that are common among reading groups and teleradiology providers across the United States.

UW Medicine

UW Medicine (UWM), a health system in Seattle, Washington, recently acquired an existing Mach7 customer, and saw the value in the Mach7 Platform. As a result, UWM has purchased a license to expand its use of the Mach7 Platform from this single facility into their greater health system. The Mach7 Platform will provide interoperability workflows between their modalities (CT, MRI, etc.) and ASX Announcement 14 August 2019 their existing PACS systems. In addition, the health system sees the value of the Mach7 Platform as a solution that will allow it to grow and solve many of their current challenges.

Sentara Halifax Regional Hospital

Sentara Healthcare, Mach7’s long-time customer, has contracted with Mach7 to migrate approximately 700,000 studies from its PACS at one of their recently -acquired hospitals, Sentara Halifax Regional Hospital. This is part of the process of fully implementing the modernized PACS solution at Sentara by Mach7 and its business partner, Client Outlook.

Achievement of Cashflow Breakeven Target On-track

23 July 2019 : Cash-flow 12-month Target On-track

In March this year, Mach7 announced a free cash-flow break-even target for the ensuing 12-month period (ending February 2020)

The Company’s cash position has grown since that target was announced, and the Company is on-track to be free cash-flow break-even for the above stated 12-month period.

Through the 12-month target period free cash-flow will continue to fluctuate from quarter to quarter, largely due to the timing of support contract renewals and payment terms for new sales.

Mach7 Contracts with Advocate Aurora Health ...

" ASX:M7T is pleased to announce that it has signed a Software and Services Agreement with Advocate Aurora Health (AAH), an integrated healthcare network headquartered in Milwaukee, Wisconsin. The agreement has a minimum total contract value of A$5.7 million across a five-yearterm. Importantly, A$550k per annum will be added to the Company’s annual recurring revenue, taking the total annual recurring revenue under contract to A$8.4 million per annum. AAH has contracted with Mach7 for its Enterprise Imaging Platform to store and manage images across its healthcare network. Along with the Mach7 Platform, AAH also purchased the migration engine to migrate ~3.5 petabytes of data. This deal is one of Mach7’s largest to date within the US,and AAH is now one of the Company’s largest US customers, demonstrating that Mach7 has an increasing influence and market share in the US market. "